目标: 确定 MPN 患者的最佳治疗方法。 分析目前对分子反应的了解,将其作为临床意义的终点(如 MPN 中的总体生存率、无白血病生存率、无血栓生存率)的替代终点。 讨论 MPN 干细胞或造血干细胞微环境的潜在脆弱性,可以利用这些脆弱性进一步优化 MPN 治疗。
Pillsbury Winthrop Shaw Pittman LLP,由 Matthew G. Jeweler、Mark J. Plumer、W. Kirk Gandy、Barry Fleishman、Aaron D. Coombs、William C. Miller 和 Jeffrey W. Mikoni 代表;Hunton & Williams LLP,由 A. Todd Brown 和 Ryan G. Rich 代表,代表原告 Duke Energy Carolinas, LLC 和 Duke Energy Progress, LLC。Rivkin Radler LLP,由 Steven Zuckermann、Alan S. Rutkin、George D. Kappus、Greg E. Mann 和 Gregory J. Klubok 代表;Goldberg Segalla,由 David G. Harris, II 和 David L. Brown 代表,代表被告 Associated Electric and Gas Insurance Services Ltd.、Berkshire Hathaway Direct Insurance Company 和 TIG Insurance Company 代表。 Squire Patton Boggs (US) LLP,由 Paul Kalish 和 Eridania Perez 代理,以及 McAngus Goudelock & Courie,由 Jeffrey Kuykendal 代理,代表被告 Allianz Global Risks US Insurance Company、Allianz Underwriters Insurance Company 和 Fireman's Fund Insurance Company。
value 2,000 200 2 99.2% 6.1% 100.0% 6.5% 3,000 400 2 97.8% 5.0% 100.0% 5.0% 4,000 600 2 96.4% 4.1% 98.7% 4.1% 5,000 800 2 95.1% 3.4% 95.7% 3.8% 2,000 300 4 99.5% 6.1% 99.9% 6.1% 3,000 600 4 99.8% 5.0% 99.8% 5.1%4,000 1,200 4 98.5%4.1%98.8%4.3%5,000 2,400 2,400 4 87.3%3.4%94.0%3.7%6,000 3,200 3,200 4 73.5%2.9%88.4%3.3%3.3%8,000 99.4% 5.0% 100.0% 5.0% 4,000 1,200 6 97.4% 4.1% 99.3% 4.3% 5,000 2,400 6 88.7% 3.4% 95.6% 3.7% 6,000 3,200 6 79.2% 2.9% 91.7% 3.3% 8,000 3,200 6 79.2% 2.4% 91.8% 2.8% 2,000 300 8 99.6% 6.1% 99.6% 6.1% 3,000 600 8 99.6% 5.0% 99.6% 5.1% 4,000 1,200 8 98.1% 4.1% 98.3% 4.3% 5,000 2,400 8 89.6% 3.4% 94.7% 3.6% 6,000 3,200 8 79.8% 2.9% 91.0% 3.2% 8,000 3,200 8 79.8% 2.4% 92.6% 2.8% 2,000 300 12 99.8% 6.1% 100.0% 6.1% 3,000 600 12 99.5% 5.0% 99.8% 5.1% 4,000 1,200 12 97.7% 4.1% 98.3% 4.2% 5,000 2,400 12 90.2% 3.4% 94.8% 3.6% 6,000 3,200 12 82.1% 2.9% 92.1% 3.1% 8,000 3,200 12 82.1% 2.4% 92.7% 2.8%